Published in Drugs Future on September 01, 2009
Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One (2010) 1.04
Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res (2011) 0.89
Perivascular delivery of Notch 1 siRNA inhibits injury-induced arterial remodeling. PLoS One (2014) 0.86
Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition. Biomacromolecules (2013) 0.86
Peptides used in the delivery of small noncoding RNA. Mol Pharm (2014) 0.83
Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale (2013) 0.82
Small-interfering RNA-eluting surfaces as a novel concept for intravascular local gene silencing. Mol Med (2011) 0.80
Acid-Sensitive Sheddable PEGylated PLGA Nanoparticles Increase the Delivery of TNF-α siRNA in Chronic Inflammation Sites. Mol Ther Nucleic Acids (2016) 0.80
Development of streptavidin-based nanocomplex for siRNA delivery. Mol Pharm (2013) 0.79
Zinc Finger Nucleases: Tailor-made for Gene Therapy. Drugs Future (2012) 0.79
Effects of RNA silencing of matrix metalloproteinase-2 on the growth of esophageal carcinoma cells in vivo. Oncol Lett (2016) 0.75
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (2000) 23.17
Argonaute2, a link between genetic and biochemical analyses of RNAi. Science (2001) 15.32
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther (1999) 8.28
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci U S A (2007) 7.50
RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science (1999) 6.97
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul (2001) 6.59
Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med (2004) 6.48
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol (2006) 6.30
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 5.99
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 5.21
High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther (1999) 5.17
Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A (2004) 4.95
siRNA function in RNAi: a chemical modification analysis. RNA (2003) 4.93
Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA (2006) 4.72
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol (2007) 4.02
Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem (2000) 4.02
Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol (2004) 3.67
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science (2008) 3.51
Cationic liposome-mediated transfection. Nature (1989) 3.46
Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res (2000) 3.41
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res (2003) 3.39
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A (2007) 3.30
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A (2005) 3.24
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res (2006) 3.22
Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem (1996) 3.18
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 3.03
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol (2000) 2.98
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 2.83
Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther (2004) 2.82
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
Aptamer mediated siRNA delivery. Nucleic Acids Res (2006) 2.77
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res (2004) 2.72
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm (2008) 2.71
RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther (2005) 2.68
Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci (2005) 2.47
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology (2005) 2.41
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res (2007) 2.30
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
siRNA and innate immunity. Oligonucleotides (2009) 2.28
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A (2007) 2.27
Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem (2003) 2.23
Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci (2004) 2.22
Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A (2004) 2.21
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
The protamine family of sperm nuclear proteins. Genome Biol (2007) 2.17
Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release (2008) 2.15
Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther (2008) 2.06
Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol (2004) 2.05
Chemical modification of siRNAs for in vivo use. Oligonucleotides (2008) 2.03
siRNA and isRNA: two edges of one sword. Mol Ther (2006) 2.02
Hydrodynamic gene delivery: its principles and applications. Mol Ther (2007) 2.01
Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci U S A (1994) 1.98
Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther (2004) 1.97
Cell penetration by transportan. FASEB J (1998) 1.93
Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol (2005) 1.93
Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A (2004) 1.91
Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther (1996) 1.87
siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol (2009) 1.86
2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther (2007) 1.85
Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry (2007) 1.83
Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2004) 1.82
Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther (2006) 1.79
Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol (2009) 1.77
Efficient gene transfer by histidylated polylysine/pDNA complexes. Bioconjug Chem (1999) 1.76
Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol (2004) 1.70
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol Bioeng (2008) 1.60
Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol (2009) 1.59
Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther (2008) 1.59
Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett (2005) 1.58
Downloadable computer models for renal replacement therapy. Kidney Int (2006) 1.56
Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem (2001) 1.53
PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb) (2006) 1.50
Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther (2001) 1.47
PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release (2006) 1.44
Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett (2004) 1.41
Computer-assisted hydrodynamic gene delivery. Mol Ther (2008) 1.40
Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes. Hum Gene Ther (1999) 1.39
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther (2006) 1.38
A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J Control Release (2006) 1.37
Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther (1998) 1.36
Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume. Gene Ther (2006) 1.35
Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev (2007) 1.34
Studies on protein uptake by isolated tumor cells. 3. Apparent stimulations due to pH, hypertonicity, polycations, or dehydration and their relation to the enhanced penetration of infectious nucleic acids. J Cell Biol (1967) 1.33
Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res (2008) 1.31
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 3.03
Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med (2005) 2.55
Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol (2004) 1.70
Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today (2006) 1.32
In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet (2005) 1.30
Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus. Am J Pathol (2012) 1.19
Human rhomboid family-1 gene silencing causes apoptosis or autophagy to epithelial cancer cells and inhibits xenograft tumor growth. Mol Cancer Ther (2008) 1.12
Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res (2002) 1.08
Highly branched HK peptides are effective carriers of siRNA. J Gene Med (2005) 1.05
Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles. Nucleic Acids Res (2002) 1.05
Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum (2005) 1.04
Modified branched peptides with a histidine-rich tail enhance in vitro gene transfection. Nucleic Acids Res (2005) 1.03
Pharmaceutical prospects for RNA interference. Pharm Res (2004) 0.97
Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir Ther (2004) 0.95
Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol Med (2005) 0.94
Alteration in the IL-2 signal peptide affects secretion of proteins in vitro and in vivo. J Gene Med (2005) 0.93
Synthetic histidine-rich peptides inhibit Candida species and other fungi in vitro: role of endocytosis and treatment implications. Antimicrob Agents Chemother (2006) 0.91
Probing the mechanism of fusion in a two-dimensional computer simulation. Biophys J (2002) 0.88
siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr Opin Mol Ther (2003) 0.87
A branched histidine/lysine peptide, H2K4b, in complex with plasmids encoding antitumor proteins inhibits tumor xenografts. J Gene Med (2006) 0.87
Enhanced silencing and stabilization of siRNA polyplexes by histidine-mediated hydrogen bonds. Biomaterials (2013) 0.86
Histidine-lysine peptides as carriers of nucleic acids. Drug News Perspect (2007) 0.86
Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition. Biomacromolecules (2013) 0.86
DNA delivery to cells in culture using peptides. Methods Mol Biol (2004) 0.83
Cryptococcus and Trichosporon spp. are susceptible in vitro to branched histidine- and lysine-rich peptides (BHKPs). J Antimicrob Chemother (2011) 0.82
Transporting silence: design of carriers for siRNA to angiogenic endothelium. J Control Release (2005) 0.82
Leveraging therapeutic potential of multi-targeted siRNA inhibitors. Future Med Chem (2009) 0.81
Delivering small interfering RNA for novel therapeutics. Methods Mol Biol (2008) 0.79
Buffering capacity and size of siRNA polyplexes influence cytokine levels. Mol Ther (2012) 0.78
Increased tumor distribution and expression of histidine-rich plasmid polyplexes. J Gene Med (2014) 0.78
Enhancement of antifungal activity by integrin-targeting of branched histidine rich peptides. J Drug Target (2014) 0.78
siRNA nanoparticles: the future of RNAi therapeutics for oncology? Nanomedicine (Lond) (2014) 0.76
Direct observation of dynamic mechanical regulation of DNA condensation by environmental stimuli. Angew Chem Int Ed Engl (2014) 0.76
Application of siRNA against SARS in the rhesus macaque model. Methods Mol Biol (2008) 0.75
Polymers for drug delivery: the debate continues. Drug Discov Today (2003) 0.75